Loading…
PALI
Palisade Bio Inc
NASDAQ· Healthcare· Biotechnology
$2.00-5.21%
Key metrics
- Market cap
- $348.54M
- P/E
- 3.2x
- Forward P/E
- —
- P/B
- 2.9x
- Dividend yield
- —
- EPS
- $0.62
- ROE
- -51.37%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.54
- 52-week high
- $2.86
- 52-week low
- $0.53
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
- 14
- Denver, United States
Company description provided by Yahoo Finance.